JP2008509110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008509110A5 JP2008509110A5 JP2007524340A JP2007524340A JP2008509110A5 JP 2008509110 A5 JP2008509110 A5 JP 2008509110A5 JP 2007524340 A JP2007524340 A JP 2007524340A JP 2007524340 A JP2007524340 A JP 2007524340A JP 2008509110 A5 JP2008509110 A5 JP 2008509110A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- deoxyguanosine
- compound according
- cytotoxicity
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 8
- 230000003013 cytotoxicity Effects 0.000 claims 5
- 231100000135 cytotoxicity Toxicity 0.000 claims 5
- 239000002777 nucleoside Substances 0.000 claims 5
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010038997 Retroviral infections Diseases 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- XSSYCIGJYCVRRK-RQJHMYQMSA-N (-)-carbovir Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1C[C@H](CO)C=C1 XSSYCIGJYCVRRK-RQJHMYQMSA-N 0.000 claims 2
- -1 2', 3'-dideoxycytidine-2'-deoxy-5'-guanosyl triphosphate Chemical compound 0.000 claims 2
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 claims 2
- PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 claims 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 claims 2
- OCLZPNCLRLDXJC-NTSWFWBYSA-N 2-amino-9-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](CO)O1 OCLZPNCLRLDXJC-NTSWFWBYSA-N 0.000 claims 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 2
- 102100034343 Integrase Human genes 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 108010017842 Telomerase Proteins 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 229960001997 adefovir Drugs 0.000 claims 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 2
- 229960005305 adenosine Drugs 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 239000010836 blood and blood product Substances 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229960004556 tenofovir Drugs 0.000 claims 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 2
- 229960002555 zidovudine Drugs 0.000 claims 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 2
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- 229920000388 Polyphosphate Polymers 0.000 claims 1
- 208000006994 Precancerous Conditions Diseases 0.000 claims 1
- QGYIFQKZZSSUCR-OBXARNEKSA-N [[(2s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C[C@H]1O QGYIFQKZZSSUCR-OBXARNEKSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- 229940125691 blood product Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960002436 cladribine Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 229960005304 fludarabine phosphate Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000001205 polyphosphate Substances 0.000 claims 1
- 235000011176 polyphosphates Nutrition 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 229960003087 tioguanine Drugs 0.000 claims 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
- 239000001226 triphosphate Substances 0.000 claims 1
- 235000011178 triphosphate Nutrition 0.000 claims 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 1
- 229940048102 triphosphoric acid Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000173A ITFI20040173A1 (it) | 2004-08-03 | 2004-08-03 | Profarmaci attivati da dna polimerasi dipendenti da rna |
| PCT/EP2005/053765 WO2006013203A2 (en) | 2004-08-03 | 2005-08-02 | Prodrugs activated by rna-dependent dna-polymerases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008509110A JP2008509110A (ja) | 2008-03-27 |
| JP2008509110A5 true JP2008509110A5 (enExample) | 2008-09-04 |
Family
ID=35589591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007524340A Pending JP2008509110A (ja) | 2004-08-03 | 2005-08-02 | Ｒｎａ依存性ｄｎａポリメラーゼで活性化されるプロドラッグ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8110676B2 (enExample) |
| EP (1) | EP1778254A2 (enExample) |
| JP (1) | JP2008509110A (enExample) |
| CN (1) | CN101031308A (enExample) |
| AU (1) | AU2005268775A1 (enExample) |
| CA (1) | CA2575520A1 (enExample) |
| IT (1) | ITFI20040173A1 (enExample) |
| WO (1) | WO2006013203A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| CN102014919B (zh) * | 2008-03-03 | 2015-02-25 | 托斯克公司 | 减少毒性的甲氨蝶呤佐剂及其使用方法 |
| ES2874774T3 (es) | 2011-12-22 | 2021-11-05 | Geron Corp | Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| US20190100553A1 (en) * | 2016-04-12 | 2019-04-04 | The Board Of Trustees Of The Leland Stanford Junior University | Direct activity assays and compositions for nucleotide pool sanitizing enzymes |
| WO2023007019A1 (en) * | 2021-07-30 | 2023-02-02 | CureVac SE | Cap analogs having an acyclic linker to the guanine derivative nucleobase |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR880000094B1 (ko) * | 1984-12-07 | 1988-02-23 | 보령제약 주식회사 | 뉴클레오시드 유도체의 제조방법 |
| JPH0920792A (ja) * | 1995-07-11 | 1997-01-21 | Soyaku Gijutsu Kenkyusho:Kk | ヌクレオチドダイマー |
| JP2005525358A (ja) * | 2002-02-28 | 2005-08-25 | ビオタ インコーポレーティッド | ヌクレオチド模倣体およびそのプロドラッグ |
| WO2004064782A2 (en) * | 2003-01-16 | 2004-08-05 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
-
2004
- 2004-08-03 IT IT000173A patent/ITFI20040173A1/it unknown
-
2005
- 2005-08-02 WO PCT/EP2005/053765 patent/WO2006013203A2/en not_active Ceased
- 2005-08-02 US US11/659,269 patent/US8110676B2/en not_active Expired - Fee Related
- 2005-08-02 EP EP05779043A patent/EP1778254A2/en not_active Withdrawn
- 2005-08-02 AU AU2005268775A patent/AU2005268775A1/en not_active Abandoned
- 2005-08-02 CA CA002575520A patent/CA2575520A1/en not_active Abandoned
- 2005-08-02 JP JP2007524340A patent/JP2008509110A/ja active Pending
- 2005-08-02 CN CNA2005800260597A patent/CN101031308A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mahmoud et al. | Antiviral nucleoside and nucleotide analogs: a review | |
| US8895531B2 (en) | 2′-fluoronucleoside phosphonates as antiviral agents | |
| CN104640444B (zh) | 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药 | |
| US7247621B2 (en) | Antiviral phosphonate compounds and methods therefor | |
| JP2004513070A5 (enExample) | ||
| JP3802057B2 (ja) | ヌクレオシド一リン酸の新規の脂質エステル及び免疫抑制薬としてのその利用 | |
| de Clercq | Milestones in the discovery of antiviral agents: nucleosides and nucleotides | |
| JP4294870B2 (ja) | Ｂ型肝炎の治療のためのβ−Ｌ−２’−デオキシ−ヌクレオシド | |
| CN103403014B (zh) | O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途 | |
| KR20230170015A (ko) | 항바이러스제로서의 뉴클레오시드 및 뉴클레오티드 유사체 | |
| JP2008505902A5 (enExample) | ||
| JP2002505333A5 (enExample) | ||
| KR20030032927A (ko) | 뉴클레오시드 화합물 및 이들의 용도 | |
| JP2005503358A5 (enExample) | ||
| JP2008523098A5 (enExample) | ||
| JP2006516949A5 (enExample) | ||
| KR100256144B1 (ko) | 아실화된 피리미딘 누클레오사이드를 이용한 화학요법제 및 항비루스제의 독성의 치료 | |
| MC1742A1 (fr) | Procede pour preparer un derive de 3'-azido-3'desoxythymigline et procede pour preparer une formulation pharmaceutique le contenant | |
| CA2503730A1 (en) | Cytarabine monophosphate prodrugs | |
| JP2004506606A (ja) | 抗ウイルスピリミジンヌクレオシド類 | |
| JP2006507308A5 (enExample) | ||
| JP2008509110A5 (enExample) | ||
| JP2008069182A5 (enExample) | ||
| Lech-Maranda et al. | Pharmacological and clinical studies on purine nucleoside analogs-new anticancer agents | |
| US8110676B2 (en) | Prodrugs activated by RNA-dependent DNA-polymerases |